Gulf International Bank UK Ltd Sells 4,741 Shares of CVS Health Co. (NYSE:CVS)

Gulf International Bank UK Ltd lowered its stake in CVS Health Co. (NYSE:CVSFree Report) by 4.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 97,142 shares of the pharmacy operator’s stock after selling 4,741 shares during the period. Gulf International Bank UK Ltd’s holdings in CVS Health were worth $6,108,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Cullinan Associates Inc. raised its holdings in CVS Health by 43.8% in the 3rd quarter. Cullinan Associates Inc. now owns 122,682 shares of the pharmacy operator’s stock worth $7,125,000 after acquiring an additional 37,395 shares during the period. Deerfield Management Company L.P. Series C bought a new position in CVS Health in the 2nd quarter worth $57,584,000. CX Institutional raised its holdings in CVS Health by 698.0% in the 3rd quarter. CX Institutional now owns 74,609 shares of the pharmacy operator’s stock worth $4,691,000 after acquiring an additional 65,259 shares during the period. Susquehanna Fundamental Investments LLC grew its holdings in CVS Health by 27.9% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 665,451 shares of the pharmacy operator’s stock valued at $39,302,000 after buying an additional 145,158 shares during the last quarter. Finally, AustralianSuper Pty Ltd increased its position in CVS Health by 11.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 1,537,791 shares of the pharmacy operator’s stock worth $96,696,000 after buying an additional 151,901 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 1.2 %

NYSE:CVS opened at $55.33 on Wednesday. The stock’s fifty day moving average price is $59.51 and its two-hundred day moving average price is $59.29. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.66 and a current ratio of 0.86. The company has a market cap of $69.60 billion, a price-to-earnings ratio of 9.85, a P/E/G ratio of 0.82 and a beta of 0.55. CVS Health Co. has a 52-week low of $52.77 and a 52-week high of $83.25.

CVS Health (NYSE:CVSGet Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The pharmacy operator reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.10. The company had revenue of $91.23 billion for the quarter, compared to the consensus estimate of $91.41 billion. CVS Health had a return on equity of 12.72% and a net margin of 1.98%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.21 EPS. On average, analysts anticipate that CVS Health Co. will post 6.41 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Monday, October 21st were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.81%. The ex-dividend date was Monday, October 21st. CVS Health’s dividend payout ratio (DPR) is currently 47.33%.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on CVS shares. Evercore ISI boosted their target price on shares of CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Royal Bank of Canada restated an “outperform” rating and set a $68.00 price target on shares of CVS Health in a research note on Wednesday, September 4th. Mizuho cut their price target on CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Deutsche Bank Aktiengesellschaft cut their price target on CVS Health from $64.00 to $63.00 and set a “hold” rating for the company in a report on Friday, August 9th. Finally, Barclays cut their price target on CVS Health from $82.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. Nine analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $73.11.

Get Our Latest Analysis on CVS Health

CVS Health Profile

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

See Also

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSFree Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.